Tumor vaccines for pediatric sarcomas

Osteogenesis imperfecta and growth
There is limited information on linear growth and weight in the various types of osteogenesis imperfecta (OI). Germain-Lee and coauthors report cross-sectional anthropometric data from 343 subjects with different OI types. Growth velocities of children with type I OI were found to taper off near puberty; those of children with type III OI decelerate before 5 years of age. The linear growth patterns, in addition to the marked increase in weight over time, indicate a need for lifestyle modifications early in childhood. See page 489
Next-generation sequencing for DRTA Primary distal renal tubular acidosis (DRTA) is a rare disease caused by loss-of-function mutations in at least three genes involved in urinary distal acidification. Next-generation sequencing (NGS) facilitates the search for mutations in DRTA patients and helps characterize the genetic and clinical spectra of the disease. Gómez and colleagues sequenced exons of the three genes by ultrasequencing for 10 DRTA patients and found a total of 13 mutations. This study shows that NGS is cost-effective for the analysis of DRTA genes. See page 496
Long-term evaluation after neonatal kidney injury
The neonatal acute kidney injury workshop sponsored by the National Institutes of Health in April 2013 provided a platform for discussing our understanding of the long-term renal consequences of chronic kidney disease (CKD) in newborns. This special article by Askenazi and coauthors examines the feasibility of conducting large multicenter studies of CKD. See page 502
Genetics of human hematopoiesis
In the review that won the 2015 Young Investigator Award, Wakabayashi and Sankaran observe that the majority of studies on hematopoiesis have been conducted primarily in animal models, but significant divergence between species is increasingly recognized at the genomic level. The authors discuss studies of humans and human variation that provide additional insight into blood production and disorders, and look to advancements in therapies. See page 366
